Acadia Pharmaceuticals Inc

NASDAQ: ACAD
$17.66
+$0.46 (+2.7%)
Closing Price on November 8, 2024

ACAD Articles

Acadia Pharmaceuticals shares rose sharply early Monday after the firm announced that its late-stage dementia study met its primary endpoint.
Acadia Pharmaceuticals shares dropped on Tuesday after the firm announced results from its late-stage study for the treatment of adult schizophrenia patients.
Acadia Pharmaceuticals shares dipped on Wednesday despite announcing positive top-line results from its Clarity mid-stage study in major depressive disorder (MDD).
Acadia Pharmaceuticals shares popped after the company announced that the FDA completed a postmarketing review and issued a clear statement reaffirming the positive benefit-risk profile of Nuplazid...
The top analyst upgrades, downgrades and initiations seen on Friday include AMD, Alcoa, AT&T, Darden Restaurants, Micron Technology, New Age Beverages, Nike, Novavax, Pier 1 Imports and Under...
With 2018 coming to a close in just a few months, Merrill Lynch is taking a close look at the biotech industry and what key catalysts to expect before 2019.
The top analyst upgrades, downgrades and initiations seen on Thursday include Aetna, Analog Devices, Lowe's, Merck, Pfizer, Plug Power, Qualcomm and Target.
Ultra Petroleum, Coty, e.l.f. Beauty, and Acadia Pharmaceuticals all posted new 52-week lows Thursday.
24/7 Wall St. tracked six companies that saw three or more analyst downgrades or price target cuts on Thursday, August 9, 2018.
The top analyst upgrades, downgrades and other research calls from Thursday include Applied Materials, Extreme Networks, Mylan, NXP, Roku, Seagate, Yelp and Zynga.
The top analyst upgrades, downgrades and other research calls from Tuesday include Broadcom, CBS, Etsy, Illumina, PulteGroup, SeaWorld, Wynn Resorts and Zillow.
Mannkind, Tesaro, Acadia Pharmaceuticals, and Diebold Nixdorf all posted new 52-week lows Monday.
LendingClub, Coca-Cola, Acadia Pharmaceuticals, and Bristol-Myers Squibb all posted new 52-week lows Wednesday.
Acadia Pharmaceuticals, Veo, Sibanye Gold, and Incyte Pharmaceuticals all posted new 52-week lows Monday.
A new Merrill Lynch research report makes the case that four top biotech companies the firm covers have some powerful catalysts that could drive performance this year.